Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15754736rdf:typepubmed:Citationlld:pubmed
pubmed-article:15754736lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C2003888lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C0001206lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C0021665lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C1272755lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:15754736lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:15754736pubmed:issue11lld:pubmed
pubmed-article:15754736pubmed:dateCreated2005-3-9lld:pubmed
pubmed-article:15754736pubmed:abstractTextin acromegaly, the criteria for the cure of the disease after neurosurgery have become tighter and tighter. In contrast, the evaluation of control of disease activity during medical treatment is based upon the normalisation of IGF-I levels and epidemiological criteria, i.e. lessening GH (assessed by RIA) to levels reported to normalise increased mortality. The aim of this study was to evaluate GH and IGF-I suppression during prolonged SS analogues (SA) treatment. The concordance between "safe" GH and normalised IGF-I levels during SA was also assessed, according to gender and gonadal status.lld:pubmed
pubmed-article:15754736pubmed:languageenglld:pubmed
pubmed-article:15754736pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15754736pubmed:citationSubsetIMlld:pubmed
pubmed-article:15754736pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15754736pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15754736pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15754736pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15754736pubmed:statusMEDLINElld:pubmed
pubmed-article:15754736pubmed:monthDeclld:pubmed
pubmed-article:15754736pubmed:issn0391-4097lld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:GhigoEElld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:CozziRRlld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:PaganiGGlld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:MontiniMMlld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:AttanasioRRlld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:LoliPPlld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:GrottoliSSlld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:PedroncelliA...lld:pubmed
pubmed-article:15754736pubmed:authorpubmed-author:GascoVVlld:pubmed
pubmed-article:15754736pubmed:issnTypePrintlld:pubmed
pubmed-article:15754736pubmed:volume27lld:pubmed
pubmed-article:15754736pubmed:ownerNLMlld:pubmed
pubmed-article:15754736pubmed:authorsCompleteYlld:pubmed
pubmed-article:15754736pubmed:pagination1040-7lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:meshHeadingpubmed-meshheading:15754736...lld:pubmed
pubmed-article:15754736pubmed:year2004lld:pubmed
pubmed-article:15754736pubmed:articleTitleTreatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?lld:pubmed
pubmed-article:15754736pubmed:affiliationDivision of Endocrinology, Niguarda Hospital, Milan, Italy. renatocozzi@tiscali.itlld:pubmed
pubmed-article:15754736pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15754736pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15754736pubmed:publicationTypeMulticenter Studylld:pubmed